Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin
- 1 February 1994
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (2) , 211-216
- https://doi.org/10.1128/aac.38.2.211
Abstract
The Oxyrase agar dilution method (Oxyrase, Inc., Mansfield, Ohio), which provides an anaerobic environment without added CO2, was compared with the reference agar dilution method recommended by the National Committee for Clinical Laboratory Standards (anaerobic chamber with 10% CO2) to test the susceptibilities of 302 gram-negative and gram-positive anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. For erythromycin, the overall MIC for 50% of isolates tested (MIC50) was 0.5 micrograms/ml and the MIC90 was 8.0 micrograms/ml by the Oxyrase method, whereas they were 4.0 and 64.0 micrograms/ml, respectively, under standard anaerobic conditions with CO2. At a breakpoint of 4.0 micrograms/ml, 88% of strains were susceptible to erythromycin by the Oxyrase method, whereas 63% were susceptible in the chamber. The corresponding MIC50s and MIC90s of azithromycin, clarithromycin, and roxithromycin by the Oxyrase method were 0.5 and 8.0, 0.25 and 4.0, and 0.5 and 16.0 micrograms/ml, respectively, whereas in the chamber they were 4.0 and > 64.0, 2.0 and 64.0, and 2.0 and 64.0 micrograms/ml, respectively. At a breakpoint of 8.0 micrograms/ml for these three drugs, 89, 92, and 85% of the isolates, respectively, were susceptible by the Oxyrase method, whereas 67%, 72, and 68% of the isolates, respectively, were susceptible in the chamber. Most strains resistant to all four compounds by both methods were Bacteroides distasonis, Fusobacterium mortiferum, Fusobacterium varium and non-Clostridium perfringens Clostridium species. Results of the study may lead to a reappraisal of the role played by macrolides and azalides in the treatment of anaerobic infections.Keywords
This publication has 30 references indexed in Scilit:
- Comparative in-vitro activity of azithromycin, macrolides (erythromycin, clarithromycin and spiramycin) and streptogramin RP 59500 against oral organismsJournal of Antimicrobial Chemotherapy, 1992
- Macrolide pharmacokinetics and dose scheduling of roxithromycinDiagnostic Microbiology and Infectious Disease, 1992
- Resistance of Peptostreptococcus spp. to macrolides and lincosamides: inducible and constitutive phenotypesAntimicrobial Agents and Chemotherapy, 1992
- Clarithromycin, a unique macrolide: A pharmacokinetic, microbiological, and clinical overviewDiagnostic Microbiology and Infectious Disease, 1992
- Influence of the test medium on azithromycin and erythromycin regression statisticsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1991
- In-vitro potency of azithromycin against Gram-negative bacilli is method-dependentJournal of Antimicrobial Chemotherapy, 1991
- In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycinAntimicrobial Agents and Chemotherapy, 1988
- Inducible macrolides-lincosamides-streptogramin B resistance in Bacteroides speciesAntimicrobial Agents and Chemotherapy, 1987
- In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolideAntimicrobial Agents and Chemotherapy, 1986
- Gram-Negative Anaerobic Bacilli: Their Role in Infection and Patterns of Susceptibility to Antimicrobial Agents. II. Little-Known Fusobacterium Species and Miscellaneous GeneraClinical Infectious Diseases, 1981